XENON PHARMACEUTICALS INC (XENE) Stock Price, Quote, News and Overview
NASDAQ:XENE - Nasdaq - CA98420N1050 - Common Stock - Currency: USD
XENE Quote, Performance and Key Statistics
39.73
+0.35 (+0.89%)
The current stock price of XENE is 39.73 USD. In the past month the price decreased by -0.63%. In the past year, price decreased by -19.67%.
XENE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About XENE
Company Profile
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 251 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. The company has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Company Info
XENON PHARMACEUTICALS INC
3650 Gilmore Way
Vancouver BRITISH COLUMBIA V5G 48W CA
CEO: Simon Pimstone
Employees: 255
Company Website: https://www.xenon-pharma.com/
Investor Relations: https://investor.xenon-pharma.com/
Phone: 16044843300
XENON PHARMACEUTICALS INC / XENE FAQ
What is the stock price of XENON PHARMACEUTICALS INC today?
The current stock price of XENE is 39.73 USD. The price increased by 0.89% in the last trading session.
What is the ticker symbol for XENON PHARMACEUTICALS INC stock?
The exchange symbol of XENON PHARMACEUTICALS INC is XENE and it is listed on the Nasdaq exchange.
On which exchange is XENE stock listed?
XENE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for XENON PHARMACEUTICALS INC stock?
22 analysts have analysed XENE and the average price target is 58.85 USD. This implies a price increase of 48.12% is expected in the next year compared to the current price of 39.73. Check the XENON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is XENON PHARMACEUTICALS INC worth?
XENON PHARMACEUTICALS INC (XENE) has a market capitalization of 3.03B USD. This makes XENE a Mid Cap stock.
How many employees does XENON PHARMACEUTICALS INC have?
XENON PHARMACEUTICALS INC (XENE) currently has 255 employees.
What are the support and resistance levels for XENON PHARMACEUTICALS INC (XENE) stock?
XENON PHARMACEUTICALS INC (XENE) has a support level at 39.68 and a resistance level at 40.48. Check the full technical report for a detailed analysis of XENE support and resistance levels.
Is XENON PHARMACEUTICALS INC (XENE) expected to grow?
The Revenue of XENON PHARMACEUTICALS INC (XENE) is expected to decline by -85.78% in the next year. Check the estimates tab for more information on the XENE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy XENON PHARMACEUTICALS INC (XENE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XENE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XENE, evaluating the profitability, health, valuation and growth aspects
- XENON PHARMACEUTICALS INC (XENE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XENON PHARMACEUTICALS INC (XENE) Sales and EPS estimates to see what analysts future expectations are.
- XENON PHARMACEUTICALS INC (XENE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XENON PHARMACEUTICALS INC (XENE) Insider and Institutional Ownership to learn about the owners and their transactions.
- XENON PHARMACEUTICALS INC (XENE) Stock Chart to make your own analysis
- XENON PHARMACEUTICALS INC (XENE) Latest news and press-releases to stay up to date.
Does XENON PHARMACEUTICALS INC (XENE) stock pay dividends?
XENE does not pay a dividend.
When does XENON PHARMACEUTICALS INC (XENE) report earnings?
XENON PHARMACEUTICALS INC (XENE) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of XENON PHARMACEUTICALS INC (XENE)?
XENON PHARMACEUTICALS INC (XENE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.82).
What is the Short Interest ratio of XENON PHARMACEUTICALS INC (XENE) stock?
The outstanding short interest for XENON PHARMACEUTICALS INC (XENE) is 4.73% of its float. Check the ownership tab for more information on the XENE short interest.
XENE Technical Analysis
XENE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XENE. While XENE has a great health rating, there are worries on its profitability.
XENE Financial Highlights
Over the last trailing twelve months XENE reported a non-GAAP Earnings per Share(EPS) of -2.82. The EPS decreased by -6.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.52% | ||
| ROE | -23.58% | ||
| Debt/Equity | 0 |
XENE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to XENE. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of -16.36% and a revenue growth -85.78% for XENE